Michael Cookson to Administration, Intravesical
This is a "connection" page, showing publications Michael Cookson has written about Administration, Intravesical.
Connection Strength
0.403
-
National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer. J Urol. 2012 May; 187(5):1571-6.
Score: 0.098
-
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.
Score: 0.057
-
Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol. 2022 Oct; 5(5):505-516.
Score: 0.050
-
Eosinophilic cystitis presenting as a recurrent symptomatic bladder mass following intravesical mitomycin C therapy. J Urol. 2002 Apr; 167(4):1795.
Score: 0.049
-
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.
Score: 0.048
-
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
Score: 0.045
-
Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. Eur Urol. 2015 May; 67(5):876-88.
Score: 0.030
-
Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol. 1992 Sep; 148(3):797-801.
Score: 0.025